# **Deloitte.**



### Prescription Drug Pricing Reform Inflation Reduction Act of 2022

Signed into law on August 16, 2022

The Inflation Reduction Act of 2022 (IRA) establishes new measures and regulatory authorities to control drug costs across the Medicare program

"The IRA is a historic piece of legislation. There hasn't been such consequential legislation addressing drug costs since the passage of the Medicare Modernization Act in 2003, establishing the original drug benefit in Medicare nearly 20 years ago."

- Anne Phelps, Principal US Health Care Policy Leader Deloitte & Touche LLP

### Drug Price Negotiation

For the first time in the history of the Medicare drug program, the Centers for Medicare and Medicaid Services (CMS) will now be required by law to negotiate directly with pharmaceutical manufacturers to control the rising prices of certain high-cost drugs in Medicare Parts B and D


### Inflationary Price Caps

To help control the rising cost of medication for Medicare beneficiaries, **the law's inflationary provisions on Parts B and D drugs "cap" drug price annual growth rates** benchmarked against the Consumer Price Index for All Urban Consumers (CPI-U)

### Medicare Beneficiaries

The law's drug pricing provisions aim to help Medicare beneficiaries by instituting measures to control rising drug costs while lowering the existing maximum out-of-pocket under Part D, thus closing the so-called Medicare "donut hole" created under the original law in 2003

### The drug pricing provisions under the IRA are divided into five parts



# The major drug pricing provisions should be analyzed together to understand full impact

### **DRUG PRICE NEGOTIATIONS**

The Secretary of Health and Human Services (the Secretary) is required to examine and rank 100 highcost drugs to select the specific drugs for negotiation each year. The number of selected drugs starts with 10 in 2026 and expands to 15 in 2027, 15 in 2028, and 20 in 2029. If a negotiated drug comes off the list and new drugs are selected year-overyear, there may be up to 60 selected drugs by 2029.

### **INFLATION REBATES**

Beginning in 2023, drug manufacturers will be required to pay Medicare a rebate for Parts B and D drugs when prices increase faster than inflation. This applies to all Parts B and D drugs (with some exceptions). This will also apply to drugs when they come off the highcost negotiated list, setting a benchmark for future years.

#### **BENEFIT REDESIGN**

Setting the maximum out of pocket cost for Medicare beneficiaries at \$2,000 means beneficiaries will be able to afford more of their medicines but will also require CMS and private health plans to manage the catastrophic drug benefit and increased insurance risk.

### **IRA's BROADER IMPACT**

#### **DRUG MANUFACTURERS** Implications for drug manufac

Implications for drug manufacturers of high-cost medications will be critical focus, in addition to inflation rebates. Manufacturers will need to establish processes to assess financial impact, conduct negotiations with CMS, and adjust agreements with customers.

### HEALTH PLANS

MA, MA-PD, and PDP\* plans will be able to forecast drug cost impact on premiums, including future inflationary increases, and plan for increased costs in catastrophic coverage for beneficiaries.

### **HOSPITALS / PROVIDERS**

Reduction in high-price drug costs may benefit purchasing prices, while potentially decreasing revenue / margin for certain providers with higher Part B drug utilization (e.g., HOPDs\*\*, infusion centers). Additionally, 340B programs will have to assess maximum fair price negotiations against existing 340B discounts.

### HOME HEALTH

Providers administering home infusion or other medications may need to examine Part B revenue implications.



### PHARMACEUTICAL BENEFIT MANAGERS (PBMs)

Price provisions and new negotiations may cause PBMs to assess potential price shifts across Parts B, D and commercial markets.



### PHARMACIES

Purchasing and supply chain impacts may benefit pharmacies, while price constraints could have longer-term impacts to revenue growth.



### **EMPLOYERS**

Commercial plans are not included in the drug pricing provisions. Medicare price reductions may cause cost shift and/or reevaluation of drug prices in the commercial market.

### **MEDICARE BENEFICIARIES**


Out-of-pocket costs for Parts B and D generally reduced and future increases to the growth of base premiums are limited to 6% per year.

### $\mathbf{C}\,\mathbf{M}\,\mathbf{S}$

- CMS is appropriated \$3B to establish the Drug Price Negotiation Program, almost double current program management funding.
- CMS will need to issue regulations as soon as late 2022 / early 2023 to meet legislative timelines.


\*Medicare Advantage plans, Medicare Advantage Prescription Drug Plans, and Medicare Part D prescription drug plans \*\*Hospital Outpatient Departments

### The IRA fundamentally changes aspects of Medicare Parts B and D



### **Implementation begins immediately**

Based on the timelines under the IRA, stakeholders across the industry will see revenue impact beginning in 2023



### The clock is ticking.....

Stakeholders across the industry should begin analyses and preparations in 2022



### **DRUG PRICE NEGOTIATIONS**

**June 1, 2022 to May 31, 2023** – Total Expenditures of Negotiation Eligible Drugs used for initial rankings of high spend drugs

**October 1, 2023** – Deadline to enter into agreements with manufacturers of selected drugs for the initial price applicability period

### **INFLATION REBATES**

**January 1, 2021** – Initial Parts B & D Benchmark Period: CPI-U used to calculate future inflation rebates

**October 1, 2022** – Part D drugs furnished on or after this date subject to inflation rebates (1st rebate report issued July 1, 2023)

**January 1, 2023** – Part B drugs furnished on or after this date subject to inflation rebates (1st rebate report issued July 1, 2023)

### **OTHER PROVISIONS**

January 1, 2023 – No cost share for adult vaccines; subsidies for retroactive reimbursement for PDP plan sponsor and Medicare Advantage to begin 18 months following the end of the applicable plan year January 1, 2023 – Insulin copay cap capped at \$35

### **Specific questions for health care stakeholders**

### **Life Sciences**

### **Begin Analyses**

- What drugs do you manufacture that are subject to Part B & D provisions?
- Which drugs are considered selected or high-cost drug now and in the future?
- What are the revenue implications from the inflationary caps and rebates?

### **Start Preparing**

- How will you prepare for drug negotiations with CMS?
- How will negotiations affect spending allotment and cost containment? (e.g., G&A, R&D, advertising, etc.)
- How will you prepare to offset revenue impacts due to negotiations and inflation rebates?

### **Health Plans**

### **Begin Analyses**

- What high-cost drugs are on your formularies for your MA, MA-PD, and PDP plans? What is the volume of claims?
- How will inflation caps and rebates affect your actuarial calculations?
- What is your exposure for catastrophic coverage above the new \$2000 cap for beneficiaries?

### **Start Preparing**

- What processes do you need to assess lower drugs costs and actuarial impact to annual premiums?
- What processes do you need to assess new catastrophic limits and plan coverage?
- How can you increase members based on expanded drug coverage?

### **Health Care Providers**

### **Begin Analyses**

- What high-cost drugs covered under Parts B & D are most widely administered at your facilities?
- How much revenue is coming from your Hospital Outpatient Departments for Part B drugs that will be subject to negotiation and inflations caps?
- How will these pricing provisions affect revenue and margin from drug pricing programs such as 340B?


### **Start Preparing**

- What processes do you need in place to assess revenue exposure and associated risk? Supply chain impacts?
- How are you continuing to monitor reimbursement changes stemming from this legislation?

Think about your partners: How will these changes affect your relationships or contracts with other health care stakeholders?

## Contact us:

Strategic Regulatory Implementation Team at <u>HCRegulatorySupport@deloitte.com</u>



# **Deloitte.**

### Endnotes

Source referenced on all slides: H.R.5376 - Inflation Reduction Act of 2022

1. https://www.congress.gov/bill/117th-congress/house-

bill/5376/text?q=%7B%22search%22%3A%5B%22inflation+reduction+act%22%2C%22inflation%22%2C%22reduction%22%2C%2 2act%22%5D%7D&r=1&s=4

- 2. https://www.medicare.gov/what-medicare-covers/what-part-b-covers
- 3. https://www.medpac.gov/wp-content/uploads/2021/11/medpac\_payment\_basics\_21\_partb\_final\_sec.pdf
- 4. https://www.kff.org/medicare/issue-brief/relatively-few-drugs-account-for-a-large-share-of-medicare-prescription-drug-spending/
- 5. https://crsreports.congress.gov/product/pdf/IF/IF11318
- 6. https://www.rpc.senate.gov/policy-papers/medicare-part-d-the-noninterference-clause
- 7. https://www.medicareinteractive.org/get-answers/medicare-prescription-drug-coverage-part-d/medicare-part-d-costs/phasesof-part-d-coverage
- 8. https://www.democrats.senate.gov/imo/media/doc/inflation\_reduction\_act\_of\_2022.pdf

# **Deloitte.**

This presentation contains general information only and Deloitte is not, by means of this presentation, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This presentation is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor. In addition, this presentation contains the results of a survey conducted by Deloitte. The information obtained during the survey was taken "as is" and was not validated or confirmed by Deloitte.

Deloitte shall not be responsible for any loss sustained by any person who relies on this presentation.

#### **About Deloitte**

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

Copyright © 2022 Deloitte Development LLC. All rights reserved.